, exhibited an upregulation of cytotoxic T lymphocyte (CTL) killing-associated genes, T-cell activation genes, antigen-presentation and dendritic cell (DC) maturation genes, and T-cell-attracting chemokine genes, which promoted Th1 antitumor responses. By contrast, type C, with PD-L1 -and CD8B -, exhibited a low expression of T-cell-activating genes and an upregulation of cancer driver gene signaling, which suggested an immune-suppressive status. With regard to hypermutator tumors, PD-L1 + hypermutator cases exhibited a specific upregulation of the IL6 gene compared with the PD-L1
Introduction
In recent years, a novel type of cancer immunotherapy has been developed using specific monoclonal antibodies targeting immune checkpoint molecules, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed death-1 (PD-1)/PD-ligand 1 (PD-L1). This type of therapy has been applied in a number of clinical trials (1) (2) (3) (4) (5) and shows promising clinical benefits even for patients with advanced-stage disease or metastatic cancer. These accomplishments have triggered a resurgence of cancer immunotherapy and have introduced a paradigm shift in cancer treatment (6) .
With regard to the immune checkpoint blockade for PD-1/PD-L1 in clinical trials, a positive PD-L1 expression, a high mutation burden and a high microsatellite instability (MSI) status are considered to be possible biomarkers for clinical responder prediction and good prognosis in melanoma, non-small cell lung cancer and colon cancer patients treated with PD-1/PD-L1 inhibitors (3, (7) (8) (9) (10) . Additionally, tumor-infiltrating lymphocyte (TIL) or CD8 + T-cells as tumor microenvironment (TME) factors have become more important parameters for a good antitumor response and the prognosis of cancer patients (11) (12) (13) .
As for the immunological parameters associated with TME, Rooney et 4 Medical Genetics Division, and 5 Regional Resources Division, mutations of antigen presentation-related genes (14) . On the other hand, Ock et al classified solid tumors into specific immune types based on PD-L1 and CD8 gene expression data derived from the Cancer Genome Atlas (TCGA) database (15) . These researchers demonstrated that TCGA-derived large-scale RNA-sequencing data constitute an appropriate model that can be used to assess the TME, as the contamination of stromal cells surrounding the tumor would proportionally influence the TME gene expression profiles in an unbiased manner. In our previous gene expression profiling (GEP) studies in the project High-tech Omics-based Patient Evaluation (HOPE), which began in 2014 at Shizuoka Cancer Center (Shizuoka, Japan) (16, 17) , the upregulated specific gene expression associated with TIL or tumor macrophages was verified (18) partly because all tumor specimens were obtained promptly from freshly surgically resected tumors. On the other hand, frozen tumor specimens were analyzed in the TCGA study (14, 15) .
In the current study, we classified tumors registered in the HOPE project into 4 categories based on the expression level of the PD-L1 and CD8B genes according to Ock et al (15) , and the association with the immune response-associated gene panel was investigated among 4 immune-type categories for the purpose of the appropriate evaluation of immunological status.
Materials and methods
Study design. The Shizuoka Cancer Center launched project HOPE in 2014, which is based on multi-omics analyses, including whole exome sequencing (WES) and GEP. Ethical approval for the HOPE study was obtained from the institutional review board at the Shizuoka Cancer Center (authorization no. 25-33). Written informed consent was obtained from all patients enrolled in the study. All experiments using clinical samples were carried out in accordance with the Ethical Guidelines for Human Genome and Genetic Analysis Research.
Clinical specimens. Tumor tissue samples with weights of ≥0.1 g were dissected from surgical specimens, along with samples of surrounding normal tissue. The areas from which tumor samples were dissected were visually assessed as containing ≥50% tumor content.
RNA isolation and GEP analysis. The method of RNA isolation was described previously (17) . Briefly, total RNA was extracted using the miRNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA samples were quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and their quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA samples with an RNA integrity number ≥6.0 were used for microarray analysis. Labeled samples were hybridized to the SurePrint G3 Human Gene Expression 8x60 K v2 Microarray (Agilent Technologies). Hybridization signals were detected using a DNA Microarray Scanner (Agilent Technologies). Microarray analysis was performed in accordance with the MIAME guidelines (19) .
DNA isolation and WES analysis. The method of DNA isolation was described previously (17) . Briefly, DNA was extracted from tissue and blood samples using a QIAamp kit (Qiagen) and subjected to WES on the Ion Proton System (Thermo Fisher Scientific). For data analysis, single-nucleotide variants (SNVs) with quality scores <30 or depth of coverage <20 were discarded. Somatic mutations were identified by comparing the data from tumor and corresponding blood samples. Driver mutations in 138 Vogelstein driver genes (20) were defined as those identified as pathogenic in the ClinVar database. SNVs of the total exonic mutations for each sequenced tumor included nonsynonymous, synonymous, and indels/frameshift mutations.
Establishment of the immune response-associated gene panel. The content of the immune response-associated gene panel has been previously described (18) . In total, 174 immune response-associated genes [67 antigen-presenting cell (APC)-associated and T-cell-associated genes, 34 cytokine-and metabolism-associated genes, 48 tumor necrosis factor (TNF) and TNF receptor superfamily genes and 25 regulatory T-cell-associated genes] were selected and used for GEP analysis (data not shown).
Association of TME immune category with immune or cancer signal pathways. Cancer patients of each TME category were profiled for immune and cancer signaling pathways using immune-response-associated and Vogelstein driver gene expression data, respectively, by means of Ingenuity Pathway Analysis (IPA) software (version Summer 2017; Qiagen).
Statistical analysis.
The ratio of the expression intensity between the tumor tissue and surrounding normal tissue was calculated from normalized values. A ratio of >2.0 was rated as positive for gene expression. The ratio of log 2 -transformed values of the PD-L1 and CD8B genes was plotted on the vertical and horizontal axis, respectively ( The upregulated genes in expression derived from the 174 immune response-associated gene panel between TME immune type A and other types were identified using the volcano plot method. Comparing the proportion of categorical variables in each immune-type category was performed using Pearson's Chi-square test and the unpaired two-tailed t-test. Values of P<0.05 were considered significant. Data analysis was performed using GeneSpring GX software version 13.1.1 (Agilent Technologies) and Microsoft Excel.
Results
Histological distribution and TME immune type classification of cancer patients enrolled in the HOPE project. GEP was accomplished in 1,734 pairs (without metastasis) of tumors and adjacent normal tissues derived from 17 different cancer types. Colon-rectum, lung, stomach and head and neck cancers accounted for >60% of the total cases (Fig. 1A) . The proportion of TME immune types A, B, C and D were 39.2, 26.2, 18.9 and 15.7%, respectively (Fig. 1B) . The proportion of type A was >50% in breast, colon-rectum and head and neck cancers, while it was low in lung, liver and pancreatic cancers (Fig. 1C) . On the other hand, the proportion of types C and D was higher in liver, pancreas and lung cancers. No clinicopathological factors, such as age, sex, smoking habit or clinical stage, was associated with immune type categories (data not shown).
Association of Vogelstein driver gene mutations and gene amplifications with TME immune types.
We focused on somatic SNVs obtained by WES analysis and Vogelstein driver gene mutation profiling was investigated. The proportion of all Vogelstein driver gene mutations and TP53, KRAS, EGFR, PIK3CA, BRAF mutations were calculated in each TME immune type. The frequency of Vogelstein driver gene mutation had a tendency to be higher in types C and D ( Fig. 2A and Table I) , and so did the frequency of EGFR mutations. On the other hand, the frequency of TP53 and KRAS mutations was higher in type A compared with the other types. Moreover, all 64 gene amplifications, which have been reported previously as a gene list with a >5-fold change in expression and >6 copy numbers (17) , had no significant effect on the TME immune types. However, EGFR amplification exhibited a tendency to be higher in type C, similar to the EGFR mutation frequency (Fig. 2B and Table I) .
Association of immunological cell surface markers with TME immune types. (Fig. 3 and Table I ).
Association of cytolysis and helper T-cell-related cytokines
with TME immune types. The frequencies of tumors positive for immuno-activation cytokine (IFNG, TNFA and IL12), immuno-suppressive cytokine (VEGFA, TGFB1, IL6 and IL10) and cytolytic factor (GZMB and PRF1) gene expressions were high in types A (Fig. 4 and Table I ). In particular, the IFNG and GZMB gene expression rate was >50% in type A.
The identification of upregulated immune response-associated genes in TME immune type A compared with other types. A total of 46 upregulated immune response-associated genes with a >2-fold change in expression were identified using the volcano plot (Fig. 5) . These genes belonged to Th1 pathway-activating gene population, such as T-cell effector activation (FASLIG, CD40LIG, TNFSF4, TNFSF9 and TNFSF14), CTL killing (GZMB and PRF1), T-cell attraction (CCL20, CXCR6, CCL4 and CCL5), DC maturation and Th1 cytokines (IFNG, IL12, TNFA and STAT4) (Fig. 6) .
Association of TME immune types with immune or cancer signaling pathways. Based on the expression data of a panel The SNV number is shown as the mean value and was statistically compared using the Student's t-test. All other parameters were analyzed using Pearson's Chi-square test. b Gene amplification: FC≥5 and CN≥6. A P-value <0.05 was considered to indicate a statistically significant difference. TME, tumor microenvironment. of 174 immune response-associated genes, the immune pathway-specific characterization of each TME immune type was performed using IPA software in the radar chart.
Immune type A was associated with the Th1 and T-cell activation (PKC, calcium and ICOS) pathway and dendritic cell maturation signaling. On the other hand, type C exhibited a downregulation in T-cell activation signaling, although the Cdc42 and OX40 (NF-κB) signaling pathways were activated (Fig. 7A) . Moreover, radar chart analysis based on the Vogelstein driver gene expression data revealed that type C was activated with cancer signaling pathways, such as TGF-β, ERK/MAPK, NF-κB, EGF, VEGF and JAK/STAT signaling, and was suppressed with T-cell activation signaling (PI3K and p53 and apoptosis pathways). However, these tendencies were reversed in the type A group (Fig. 7B) . In terms of calculated Z scores, type A exhibited the highest score of the immuno-activation signaling pathway and the lowest score of the cancer pathway signaling.
Hypermutator-related biomarker identification based on PD-L1 and CD8B gene expression.
The frequency of the SNV number in each TME immune types is shown in Fig. 8A ) in each TME immune type are shown. Each value represents the proportion in percentage of the immune cell phenotype high (>2-fold) and low (<2-fold) expression group in each TME immune type. TME, tumor microenvironment.
was compared between hypermutator cases in each immune type using the volcano plot analysis, which indicated that the IL6 gene was upregulated in types A and B compared with type C ( Fig. 8D and E ; Table II ), and that the TREM1 gene was upregulated in type B compared with type C. Additionally, dominant genes were not recognized when we compared immune response-associated gene expression between type A and type B (Fig. 8C and Table II) .
Discussion
Regarding the immune checkpoint blockade for PD-1/PD-L1 in clinical trials, a positive PD-L1 expression, a high mutation burden, a high microsatellite instability (MSI) status and a high TIL status are considered to be possible biomarkers for clinical responder prediction and a good prognosis in a variety of solid tumors treated with PD-1/PD-L1 inhibitors (11-13). . Identification of upregulated immune response-associated genes in TME immune type A compared with other types. A total of 46 upregulated immune response-associated genes with a >2-fold change in expression were identified using the volcano plot. The upregulation of all listed genes was statistically significant (P<0.05). TME, tumor microenvironment.
The novelties about the current approach to immunological classifications by PD-L1 and CD8B expression are the following: i) profiling specific immunological marker-positive cell populations including effector and exhausted T-cells, macrophages, dendritic cells and NK cells; ii) immune response-associated gene expression-based immune pathway analysis; and iii) Vogelstein driver gene expression-based cancer signal pathway analysis.
First, genome-based immune cell characterization other than IHC or living-cell methods, such as TILs-based surface marker analysis, is not a widely used method, but few studies on GEP-based immune cell characterization in tumors have been published (21) . Thus, there is not much evidence for or against such an approach. However, it is likely that specific immune cell distribution can be recognized with the combination of other gene expression data, such as cytolytic activity, Th1 and Th2 cytokine production and other immune response-associated genes (22) (23) (24) (25) (26) (27) (28) .
Second, in this study, the association of TME immune types with immune or cancer signaling pathways was investigated based on GEP data of immune response-associated genes or Vogelstein driver genes. The radar chart demonstrating the association of each immune type with various pathways was helpful to recognize which signal pathways were associated with type A (immune activation) and type C (immune suppression), respectively.
In sum, immune type A was associated with the Th1 T-cell pathway, NK cell activation pathway, dendritic cell maturation and cancer-apoptosis activation signals, and exhibited the highest score in immune-activation signaling pathways. On the other hand, type C exhibited a downregulation of T-cell activation signaling (with the lowest score) and oncogene signal pathway activation. These results suggested that types A and C exhibited opposite characteristics of immune and cancer signal pathways. Our approach is a novel one; thus, the combination of immune-type classification and signaling pathway analysis is a better method to evaluate immunological status prior to specific cancer immunotherapies.
Furthermore, clinical information regarding survival time is suggested to be associated with the current immune type classification. The preliminary observation, demonstrated by Ock et al (15) using survival data from TCGA database, revealed that immune subtype I (PD-L1 + CD8 + ) exhibited a longer overall survival time compared with subtype III (PD-L1 + CD8 -). We are planning a similar survival analysis in the project HOPE in the near future.
In addition to a high PD-L1 expression and CD8B upregulation as TIL marker, a high load of somatic mutations (hypermutation) in the tumor is another crucial possible biomarker that can predict the good response of immune checkpoint blockade (29) (30) (31) . In this study, we divided hypermutator tumors with >500 SNV numbers into the 4 immune types (Fig. 8B) . Ock et al demonstrated that the somatic SNV number was significantly higher in immune type A. Of note, our data indicated that hypermutators were found mainly in type A (48%) and B (35%), and even some in type C (16%, PD-L1 -CD8B -), but not in type D (PD-L1 -CD8B + ). These results suggest that PD-L1 upregulation is a crucial feature for the induction of a durable CTL response against cancers and that hypermutators alone are not sufficient. Additionally, comparing immune response-associated gene expression between TME immune type A and C derived from hypermutators revealed the upregulation of specific genes, such as IL6 and GZMB. These observations may indicate that the upregulation of these immunological genes mediated by neoantigen boosting originating from hypermutation can lead to PD-L1 upregulation, resulting in a potent immune checkpoint blockade. Of note, the TREM1 gene was associated with PD-L1 expression in the absence of CD8B expression between types B and C, which suggests activated macrophage-mediated PD-L1 induction.
Prat et al analyzed FFPE-derived tumor RNA on the nCounter system using the PanCancer 730-Immune Panel and identified 23 immune-related genes or signatures linked to antitumor-response by immune checkpoint blockade and progression-free survival (32) . These 23 immune-related genes This study demonstrated that immune type A was associated with the Th1 T-cell pathway, NK cell activation pathway, DC maturation and cancer-apoptosis activation signaling, which indicated that such results are associated with immune response-activating characteristic, leading to an antitumor effect.
Finally, our approach, based on comprehensive immune response-associated gene expression data from the HOPE project, may be very informative and helpful to the evaluation of immunological status before immunotherapy and the prediction of antitumor response after immunotherapy. In the future, studies should strengthen their evidence levels by adding updated data from a multi-omics approach, specifically immunohistochemistry and clinical survival information.
